BioSpace News Archive

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2020.

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the fourth quarter and full year 2020

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2020. Three-Month Periods Ended December 31, 2020 and 2019 Net service revenue increased $50.0 million to $550.7 million compared to $500.7 million in 2019. Net income attributable to Amedisys, Inc. of $45.2 million compared to $27.7 million in 2019.

Antylia ScientificTM, a global leader in peristaltic and single use bioprocessing solutions, and a diverse portfolio of life sciences and diagnostic products for the pharma, biopharma, healthcare, and environmental markets

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced that it has acquired Simplify Medical, a privately held company and developer of the Simplify® Cervical Artificial Disc (Simplify Disc) for cervical total disc replacement (cTDR).

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, reported its financial results for the quarter and year ended December 31, 2020 and financial guidance for the year ending December 31, 2021.

STAAR Surgical CompanySTAAR Surgical Company, a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, reported financial results for the fourth quarter and fiscal year ended January 1, 2021.

Bird & Cronin Renews Group Purchasing Agreement with Intalere for Orthopedic Soft Goods and Bracing

Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the peer-reviewed publication of a study investigating the effects of the co-administration of ImmTOR nanoparticles to adeno-associated viral (AAV) vectors on transgene expression in mice

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas.